China Pharma Holdings Inc Asset Resilience Ratio
China Pharma Holdings Inc asset resilience ratio. China Pharma Holdings Inc (CPHI) has an Asset Resilience Ratio of 0.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read China Pharma Holdings Inc (CPHI) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of China Pharma Holdings Inc (2011–2023)
Asset resilience ratio of China Pharma Holdings Inc from 2011 to 2023. This chart shows how China Pharma Holdings Inc's Asset Resilience Ratio has changed over time. See CPHI FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down China Pharma Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is China Pharma Holdings Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $26.70K | 0.17% |
| Total Liquid Assets | $26.70K | 0.17% |
Asset Resilience Insights
- Limited Liquidity: China Pharma Holdings Inc maintains only 0.17% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
China Pharma Holdings Inc Industry Peers by Asset Resilience Ratio
Compare China Pharma Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
China Pharma Holdings Inc Asset Resilience Ratio by Year (2011–2023)
China Pharma Holdings Inc asset resilience ratio by year from 2011 to 2023. The table below shows the annual Asset Resilience Ratio data for China Pharma Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.40% | $65.92K | $16.47 Million | +0.32pp |
| 2022-12-31 | 0.08% | $13.78K | $17.78 Million | -0.33pp |
| 2021-12-31 | 0.40% | $91.36K | $22.65 Million | +0.15pp |
| 2020-12-31 | 0.25% | $53.74K | $21.12 Million | +0.05pp |
| 2019-12-31 | 0.21% | $45.76K | $22.24 Million | +0.16pp |
| 2018-12-31 | 0.05% | $20.58K | $45.38 Million | -0.02pp |
| 2017-12-31 | 0.07% | $39.87K | $59.95 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $78.52 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $97.22 Million | -- |
| 2014-12-31 | 0.35% | $458.00K | $132.08 Million | +0.13pp |
| 2013-12-31 | 0.21% | $336.00K | $157.61 Million | +0.15pp |
| 2012-12-31 | 0.06% | $102.00K | $163.24 Million | +0.01pp |
| 2011-12-31 | 0.05% | $84.00K | $156.39 Million | -- |
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more